ArriVent BioPharma, Inc. Common Stock Working Capital to Net Assets Ratio
ArriVent BioPharma, Inc. Common Stock working capital to net assets ratio. ArriVent BioPharma, Inc. Common Stock (AVBP) has a Working Capital to Net Assets ratio of 99.9% as of June 2026. Working capital of $366.33 Million (current assets of $394.17 Million minus current liabilities of $27.84 Million) is measured against net assets of $366.84 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ArriVent BioPharma, Inc. Common Stock (AVBP) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Working capital to net assets ratio of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. This chart shows how ArriVent BioPharma, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 99.9%, reflecting working capital of $366.33 Million against net assets of $366.84 Million USD. See ArriVent BioPharma, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
ArriVent BioPharma, Inc. Common Stock Working Capital to Net Assets Ratio by Year (2021–2025)
ArriVent BioPharma, Inc. Common Stock working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for ArriVent BioPharma, Inc. Common Stock from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see AVBP total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 99.9% | $306.95 Million | $307.22 Million | $332.90 Million | $25.95 Million | ▲ +18.5 pp |
| 2024 | 81.4% | $209.71 Million | $257.65 Million | $226.98 Million | $17.27 Million | ▼ -16.7 pp |
| 2023 | 98.0% | $148.34 Million | $151.30 Million | $159.97 Million | $11.62 Million | ▼ -1.8 pp |
| 2022 | 99.9% | $174.26 Million | $174.46 Million | $182.62 Million | $8.36 Million | ▲ +0.1 pp |
| 2021 | 99.8% | $41.13 Million | $41.22 Million | $42.95 Million | $1.82 Million | — |